Disease Landscape and Forecast 인사이트

Clarivate Epidemiology’s coverage of retinal vein occlusion (RVO) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of RVO for…

Clarivate’s Epidemiology’s coverage of retinal vein occlusion comprises epidemiological estimates of key patient populations. We report the prevalence of retinal vein occlusion for each country…

Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus. It consists of deep vein thrombosis (DVT) and pulmonary embolism (PE), depending on the location of the obstruction…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key retinal vein occlusion patient populations covering 171 countries…

Although chemotherapy has traditionally been the cornerstone of ovarian cancer treatment, angiogenesis and PARP inhibitors have revolutionized the treatment landscape, impacting prescribing…

Gout is a painful, systemic inflammatory condition caused by elevated serum uric acid (sUA) and characterized by intermittent acute flares. Treatment of acute gout flares typically involves NSAIDs…

Clarivate Epidemiology’s coverage of osteopenia (OPE) comprises epidemiological estimates of key patient populations in seven emerging pharmaceutical markets. We report the prevalence of OPE for…

Clarivate Epidemiology’s coverage of osteopenia (OPE) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany…

Clarivate’s Epidemiology’s coverage of osteopenia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of osteopenia for each…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key OPE patient populations, covering 171 countries and more than 99% of…

The renal cell carcinoma (RCC) therapy market is rapidly evolving and experiencing substantial growth, largely driven by the increasing uptake of immune checkpoint inhibitors. Combination regimens…

Clarivate Epidemiology’s coverage of marginal zone lymphoma (MZL) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…